Base de dados : MEDLINE
Pesquisa : D08.811.277.656.300.760.300 [Categoria DeCS]
Referências encontradas : 3778 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 378 ir para página                         

  1 / 3778 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29381944
[Au] Autor:Bastida JM; Cano-Mozo MT; Lopez-Cadenas F; Vallejo VE; Merchán S; Santos-Montón C; González-Calle D; Carrillo J; Martín AA; Torres-Hernández JA; González M; Martín-Herrero F; Pabón P; González-Porras JR
[Ad] Endereço:Department of Hematology, Hospital Universitario de Salamanca-IBSAL, Salamanca.
[Ti] Título:Hemorrhagic pericardial effusion as the debut of acquired hemophilia in a chronic lymphocytic leukemia patient: A case report, and a review of acquired hemophilia A-related hematological malignancies.
[So] Source:Medicine (Baltimore);96(47):e8669, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Acquired hemophilia A (AHA) is a rare bleeding disease caused by autoantibodies against factor VIII. Spontaneous bleeding symptoms usually affect the skin and muscle, while pericardial effusion is an extremely rare manifestation. In the elderly, anticoagulant treatment is frequent and bleeding symptoms are usually associated with this. CLINICAL FINDINGS: We report a hemorrhagic pericardial effusion as the AHA debut in a patient with untreated chronic lymphocytic leukemia and anticoagulated with apixaban for atrial fibrillation and chronic arterial ischemia. The patient was treated with recombinant activated factor VII to control the active bleeding and corticosteroids and cyclophosphamide to eradicate the inhibitor. In addition, a briefly review of hematological malignancies associated to acquired hemophilia was performed. PARTICULARITIES:: a) anticoagulant treatment may confuse the suspicion of AHA and its diagnosis; b) hemorrhagic pericardial effusion is an extremely rare presentation; c) bypassing agents raise the risk of thromboembolism; d) hematological malignancies rarely cause AHA (<20% of cases). CONCLUSION: A multidisciplinary team is needed to diagnose and manage AHA effectively. The use of anticoagulants may lead to the misdiagnosis of clinical symptoms. Chronic lymphocytic leukemia is one of the main causes of hematological malignancies associated. The specific treatment of CLL is still recommended in the event of active disease.
[Mh] Termos MeSH primário: Fator VIII
Fator VIIa/administração & dosagem
Hemofilia A
Leucemia Linfocítica Crônica de Células B
Derrame Pericárdico
Pericardiectomia/métodos
[Mh] Termos MeSH secundário: Idoso
Anticorpos/sangue
Testes de Coagulação Sanguínea/métodos
Coagulantes/administração & dosagem
Ciclofosfamida/administração & dosagem
Ecocardiografia/métodos
Fator VIII/análise
Fator VIII/imunologia
Hemofilia A/sangue
Hemofilia A/complicações
Hemofilia A/etiologia
Seres Humanos
Imunossupressores/administração & dosagem
Leucemia Linfocítica Crônica de Células B/complicações
Leucemia Linfocítica Crônica de Células B/diagnóstico
Masculino
Derrame Pericárdico/diagnóstico
Derrame Pericárdico/etiologia
Derrame Pericárdico/fisiopatologia
Prednisona/administração & dosagem
Radiografia Torácica/métodos
Proteínas Recombinantes/administração & dosagem
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies); 0 (Coagulants); 0 (Immunosuppressive Agents); 0 (Recombinant Proteins); 8N3DW7272P (Cyclophosphamide); 9001-27-8 (Factor VIII); AC71R787OV (recombinant FVIIa); EC 3.4.21.21 (Factor VIIa); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008669


  2 / 3778 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460818
[Au] Autor:Wurtz NR; Parkhurst BL; DeLucca I; Glunz PW; Jiang W; Zhang X; Cheney DL; Bozarth JM; Rendina AR; Wei A; Harper T; Luettgen JM; Wu Y; Wong PC; Seiffert DA; Wexler RR; Priestley ES
[Ad] Endereço:Bristol-Myers Squibb Research and Development, Princeton, NJ 08534, United States. Electronic address: nicholas.wurtz@bms.com.
[Ti] Título:Neutral macrocyclic factor VIIa inhibitors.
[So] Source:Bioorg Med Chem Lett;27(12):2650-2654, 2017 06 15.
[Is] ISSN:1464-3405
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Factor VIIa (FVIIa) inhibitors have shown strong antithrombotic efficacy in preclinical thrombosis models with limited bleeding liabilities. Discovery of potent, orally active FVIIa inhibitors has been largely unsuccessful due to the requirement of a basic P1 group to interact with Asp189 in the S1 binding pocket, limiting their membrane permeability. We have combined recently reported neutral P1 binding substituents with a highly optimized macrocyclic chemotype to produce FVIIa inhibitors with low nanomolar potency and enhanced permeability.
[Mh] Termos MeSH primário: Fator VIIa/antagonistas & inibidores
Compostos Macrocíclicos/farmacologia
Inibidores de Serino Proteinase/farmacologia
[Mh] Termos MeSH secundário: Relação Dose-Resposta a Droga
Seres Humanos
Compostos Macrocíclicos/síntese química
Compostos Macrocíclicos/química
Estrutura Molecular
Inibidores de Serino Proteinase/síntese química
Inibidores de Serino Proteinase/química
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Macrocyclic Compounds); 0 (Serine Proteinase Inhibitors); EC 3.4.21.21 (Factor VIIa)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171124
[Lr] Data última revisão:
171124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  3 / 3778 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28801460
[Au] Autor:Muehl EM; Gajsiewicz JM; Medfisch SM; Wiersma ZSB; Morrissey JH; Bailey RC
[Ad] Endereço:From the Departments of Chemistry and.
[Ti] Título:Multiplexed silicon photonic sensor arrays enable facile characterization of coagulation protein binding to nanodiscs with variable lipid content.
[So] Source:J Biol Chem;292(39):16249-16256, 2017 Sep 29.
[Is] ISSN:1083-351X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Interactions of soluble proteins with the cell membrane are critical within the blood coagulation cascade. Of particular interest are the interactions of γ-carboxyglutamic acid-rich domain-containing clotting proteins with lipids. Variability among conventional analytical methods presents challenges for comparing clotting protein-lipid interactions. Most previous studies have investigated only a single clotting protein and lipid composition and have yielded widely different binding constants. Herein, we demonstrate that a combination of lipid bilayer nanodiscs and a multiplexed silicon photonic analysis technology enables high-throughput probing of many protein-lipid interactions among blood-clotting proteins. This approach allowed direct comparison of the binding constants of prothrombin, factor X, activated factor VII, and activated protein C to seven different binary lipid compositions. In a single experiment, the binding constants of one protein interacting with all lipid compositions were simultaneously determined. A simple surface regeneration then facilitated similar binding measurements for three other coagulation proteins. As expected, our results indicated that all proteins exhibit tighter binding (lower ) as the proportion of anionic lipid increases. Interestingly, at high proportions of phosphatidylserine, the values of all four proteins began to converge. We also found that although values for all four proteins followed trends similar to those observed for the values, the variation among the proteins was much lower, indicating that much of the variation came from the kinetic binding ( ) of the proteins. These findings indicate that the combination of silicon photonic microring resonator arrays and nanodiscs enables rapid interrogation of biomolecular binding interactions at model cell membrane interfaces.
[Mh] Termos MeSH primário: Fator VIIa/metabolismo
Fator X/metabolismo
Ácidos Fosfatídicos/metabolismo
Fosfatidilcolinas/metabolismo
Fosfatidilserinas/metabolismo
Proteína C/metabolismo
Protrombina/metabolismo
[Mh] Termos MeSH secundário: Fator VIIa/química
Fator VIIa/genética
Fator X/química
Ensaios de Triagem em Larga Escala
Seres Humanos
Cinética
Bicamadas Lipídicas/química
Bicamadas Lipídicas/metabolismo
Nanoestruturas/química
Fenômenos Ópticos
Ácidos Fosfatídicos/química
Fosfatidilcolinas/química
Fosfatidilserinas/química
Análise Serial de Proteínas
Proteína C/química
Protrombina/química
Proteínas Recombinantes/química
Proteínas Recombinantes/metabolismo
Silício/química
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (1-palmitoyl-2-oleoyl-glycero-3-phosphatidic acid); 0 (Lipid Bilayers); 0 (Phosphatidic Acids); 0 (Phosphatidylcholines); 0 (Phosphatidylserines); 0 (Protein C); 0 (Recombinant Proteins); 40290-44-6 (1-palmitoyl-2-oleoylglycero-3-phosphoserine); 9001-26-7 (Prothrombin); 9001-29-0 (Factor X); EC 3.4.21.21 (Factor VIIa); TE895536Y5 (1-palmitoyl-2-oleoylphosphatidylcholine); Z4152N8IUI (Silicon)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170813
[St] Status:MEDLINE
[do] DOI:10.1074/jbc.M117.800938


  4 / 3778 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28729433
[Au] Autor:Kamikubo Y; Mendolicchio GL; Zampolli A; Marchese P; Rothmeier AS; Orje JN; Gale AJ; Krishnaswamy S; Gruber A; Østergaard H; Petersen LC; Ruf W; Ruggeri ZM
[Ad] Endereço:Department of Molecular Medicine and.
[Ti] Título:Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex.
[So] Source:Blood;130(14):1661-1670, 2017 Oct 05.
[Is] ISSN:1528-0020
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Safe and effective antithrombotic therapy requires understanding of mechanisms that contribute to pathological thrombosis but have a lesser impact on hemostasis. We found that the extrinsic tissue factor (TF) coagulation initiation complex can selectively activate the antihemophilic cofactor, FVIII, triggering the hemostatic intrinsic coagulation pathway independently of thrombin feedback loops. In a mouse model with a relatively mild thrombogenic lesion, TF-dependent FVIII activation sets the threshold for thrombus formation through contact phase-generated FIXa. In vitro, FXa stably associated with TF-FVIIa activates FVIII, but not FV. Moreover, nascent FXa product of TF-FVIIa can transiently escape the slow kinetics of Kunitz-type inhibition by TF pathway inhibitor and preferentially activates FVIII over FV. Thus, TF synergistically primes FIXa-dependent thrombin generation independently of cofactor activation by thrombin. Accordingly, FVIIa mutants deficient in direct TF-dependent thrombin generation, but preserving FVIIIa generation by nascent FXa, can support intrinsic pathway coagulation. In ex vivo flowing blood, a TF-FVIIa mutant complex with impaired free FXa generation but activating both FVIII and FIX supports efficient FVIII-dependent thrombus formation. Thus, a previously unrecognized TF-initiated pathway directly yielding FVIIIa-FIXa intrinsic tenase complex may be prohemostatic before further coagulation amplification by thrombin-dependent feedback loops enhances the risk of thrombosis.
[Mh] Termos MeSH primário: Coagulação Sanguínea
Fator VIII/metabolismo
Fator VIIa/metabolismo
Fator Xa/metabolismo
Tromboplastina/metabolismo
[Mh] Termos MeSH secundário: Fator VIIIa/metabolismo
Seres Humanos
Trombina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
72175-66-7 (Factor VIIIa); 9001-27-8 (Factor VIII); 9035-58-9 (Thromboplastin); EC 3.4.21.21 (Factor VIIa); EC 3.4.21.5 (Thrombin); EC 3.4.21.6 (Factor Xa)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170722
[St] Status:MEDLINE
[do] DOI:10.1182/blood-2017-02-767079


  5 / 3778 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28691557
[Au] Autor:Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
[Ad] Endereço:From Universitätsklinikum Bonn, Bonn, Germany (J.O.); the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.N.M.); Genentech, South San Francisco (B.K., N.V., G.G.L.), and Children's Hospital Los
[Ti] Título:Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
[So] Source:N Engl J Med;377(9):809-818, 2017 08 31.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Emicizumab (ACE910) bridges activated factor IX and factor X to restore the function of activated factor VIII, which is deficient in persons with hemophilia A. This phase 3, multicenter trial assessed once-weekly subcutaneous emicizumab prophylaxis in persons with hemophilia A with factor VIII inhibitors. METHODS: We enrolled participants who were 12 years of age or older. Those who had previously received episodic treatment with bypassing agents were randomly assigned in a 2:1 ratio to emicizumab prophylaxis (group A) or no prophylaxis (group B). The primary end point was the difference in bleeding rates between group A and group B. Participants who had previously received prophylactic treatment with bypassing agents received emicizumab prophylaxis in group C. RESULTS: A total of 109 male participants with hemophilia A with inhibitors were enrolled. The annualized bleeding rate was 2.9 events (95% confidence interval [CI], 1.7 to 5.0) among participants who were randomly assigned to emicizumab prophylaxis (group A, 35 participants) versus 23.3 events (95% CI, 12.3 to 43.9) among those assigned to no prophylaxis (group B, 18 participants), representing a significant difference of 87% in favor of emicizumab prophylaxis (P<0.001). A total of 22 participants in group A (63%) had zero bleeding events, as compared with 1 participant (6%) in group B. Among 24 participants in group C who had participated in a noninterventional study, emicizumab prophylaxis resulted in a bleeding rate that was significantly lower by 79% than the rate with previous bypassing-agent prophylaxis (P<0.001). Overall, 198 adverse events were reported in 103 participants receiving emicizumab prophylaxis; the most frequent events were injection-site reactions (in 15% of participants). Thrombotic microangiopathy and thrombosis were reported in 2 participants each (in the primary analysis) who had received multiple infusions of activated prothrombin complex concentrate for breakthrough bleeding. No antidrug antibodies were detected. CONCLUSIONS: Emicizumab prophylaxis was associated with a significantly lower rate of bleeding events than no prophylaxis among participants with hemophilia A with inhibitors. (Funded by F. Hoffmann-La Roche and Chugai Pharmaceutical; HAVEN 1 ClinicalTrials.gov number, NCT02622321 .).
[Mh] Termos MeSH primário: Anticorpos Biespecíficos/uso terapêutico
Anticorpos Monoclonais Humanizados/uso terapêutico
Hemofilia A/tratamento farmacológico
Hemorragia/prevenção & controle
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Anticorpos Biespecíficos/efeitos adversos
Anticorpos Biespecíficos/farmacocinética
Anticorpos Monoclonais Humanizados/efeitos adversos
Anticorpos Monoclonais Humanizados/farmacocinética
Fatores de Coagulação Sanguínea/efeitos adversos
Fatores de Coagulação Sanguínea/uso terapêutico
Criança
Quimioterapia Combinada
Fator VIII/imunologia
Fator VIII/uso terapêutico
Fator VIIa/uso terapêutico
Hemofilia A/imunologia
Seres Humanos
Injeções Subcutâneas
Isoanticorpos/sangue
Masculino
Meia-Idade
Proteínas Recombinantes/uso terapêutico
Trombose/induzido quimicamente
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antibodies, Bispecific); 0 (Antibodies, Monoclonal, Humanized); 0 (Blood Coagulation Factors); 0 (Isoantibodies); 0 (Recombinant Proteins); 0 (emicizumab); 37224-63-8 (prothrombin complex concentrates); 9001-27-8 (Factor VIII); EC 3.4.21.21 (Factor VIIa)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170711
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMoa1703068


  6 / 3778 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28672139
[Au] Autor:Passarelli PC; Pasquantonio G; D'Addona A
[Ad] Endereço:Resident in Oral Surgery, Catholic University of Sacred Heart of Rome, Rome, Italy. Electronic address: piercarminepassarelli@hotmail.it.
[Ti] Título:Management of Surgical Third Lower Molar Extraction and Postoperative Progress in Patients With Factor VII Deficiency: A Clinical Protocol and Focus on This Rare Pathologic Entity.
[So] Source:J Oral Maxillofac Surg;75(10):2070.e1-2070.e4, 2017 Oct.
[Is] ISSN:1531-5053
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The purpose of the present study was to analyze the management of surgical third molar extraction and postoperative progress in patients with a diagnosis of factor VII deficiency. Close collaboration between the oral-maxillofacial surgeon and hematologist will allow the team to categorize the risk and operate safely, thereby minimizing the incidence and severity of intraoperative and postoperative complications. MATERIALS AND METHODS: The present retrospective study included 7 patients with factor VII deficiency who had undergone third lower molar surgery. Their factor VII deficiency ranged from 10.5 to 21.0%. Recombinant activated factor VII (rFVIIa) (coagulation factor VIIa [recombinant]; NovoSeven RT; Novo Nordisk, Bagsvaerd, Denmark) was transfused intravenously in a single dose of 25 µg/kg body weight, 30 minutes before surgical extractions. After the surgery, betamethasone, an analgesic, and an ice pack were administered. RESULTS: Pretreatment with recombinant activated factor VII resulted in excellent hemostasis. No hemorrhagic complications and no postoperative major bleeding were observed. CONCLUSIONS: The extraction of the third lower molar appears to be a safe procedure for patients with factor VII deficiency when appropriate prophylaxis with rFVIIa is used.
[Mh] Termos MeSH primário: Perda Sanguínea Cirúrgica/prevenção & controle
Deficiência do Fator VII/complicações
Fator VIIa/uso terapêutico
Dente Serotino/cirurgia
Hemorragia Pós-Operatória/etiologia
Hemorragia Pós-Operatória/prevenção & controle
Extração Dentária
[Mh] Termos MeSH secundário: Adulto
Protocolos Clínicos
Feminino
Seres Humanos
Masculino
Proteínas Recombinantes/uso terapêutico
Estudos Retrospectivos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Recombinant Proteins); AC71R787OV (recombinant FVIIa); EC 3.4.21.21 (Factor VIIa)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:AIM; D; IM
[Da] Data de entrada para processamento:170704
[St] Status:MEDLINE


  7 / 3778 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28604077
[Au] Autor:Udvardy M
[Ad] Endereço:Belgyógyászat Intézet, Hematológia Tanszék, Debreceni Egyetem, Általános Orvostudományi Kar Debrecen, Nagyerdei krt. 98., 4032.
[Ti] Título:[Activated Factor VII - 31 years experience on clinical grounds].
[Ti] Título:Az aktivált VII. faktor ­ 31 éves klinikai alkalmazás tanulságai..
[So] Source:Orv Hetil;158(24):923-928, 2017 Jun.
[Is] ISSN:0030-6002
[Cp] País de publicação:Hungary
[La] Idioma:hun
[Ab] Resumo:The author provides an overview of the use of recombinant activated FVII (rFVIIa, Novoseven), which is used over 30 years, based upon international publications and also on some modest own experience. Standard, approved indications (inhibitory cases, Glanzmann thrombasthenia, prophylaxis experience) are in the focus of this paper, emphasizing the specially rapid and efficacious way of Novoseven therapy, drawing attention to excellent safety issues regarding very low immunogenicity along with low number of thrombogenic complications. A careful, cautious and critical evaluation of Novoseven therapy is also provided in rather special forms of critical bleeding conditions considering international recommendations and institutional registry data. Orv Hetil. 2017; 158(24): 923-928.
[Mh] Termos MeSH primário: Transtornos da Coagulação Sanguínea/tratamento farmacológico
Coagulantes/uso terapêutico
Fator VIIa/uso terapêutico
[Mh] Termos MeSH secundário: Seres Humanos
Proteínas Recombinantes/uso terapêutico
Trombastenia/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Coagulants); 0 (Recombinant Proteins); AC71R787OV (recombinant FVIIa); EC 3.4.21.21 (Factor VIIa)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170808
[Lr] Data última revisão:
170808
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170613
[St] Status:MEDLINE
[do] DOI:10.1556/650.2017.30758


  8 / 3778 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28589615
[Au] Autor:Young G; Escobar MA; Pipe SW; Cooper DL
[Ad] Endereço:Hemostasis and Thrombosis Center, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.
[Ti] Título:Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries.
[So] Source:Am J Hematol;92(9):940-945, 2017 Sep.
[Is] ISSN:1096-8652
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Self-administration of factor and bypassing agents by persons with hemophilia in the home setting is recommended to facilitate earlier intervention after bleeding episodes. The objective of this review was to summarize recombinant activated coagulation factor VII (rFVIIa) safety and efficacy data from clinical trials and patient registries documenting use in the home treatment setting in people with congenital hemophilia with inhibitors (CHwI). A total of 16 studies and registries were identified for inclusion; 14 evaluated on-demand treatment of acute bleeding episodes (865 patients, 9024 bleeding episodes) and 2 evaluated use for secondary prophylaxis (108 patients, 42,861 prophylaxis days). In the on-demand studies, efficacy was consistently high (81%-96%), and thrombotic events were uncommon (n = 3). In the secondary prophylaxis studies, rFVIIa was associated with a 45% to 59% reduction in bleeding episodes and no thrombotic events. These data support the clinical practice of administering rFVIIa in patients in the home treatment setting after initiation under a physician's care.
[Mh] Termos MeSH primário: Inibidores dos Fatores de Coagulação Sanguínea/sangue
Fator VIIa/uso terapêutico
Hemofilia A/sangue
Hemofilia A/tratamento farmacológico
Hemorragia/sangue
Hemorragia/prevenção & controle
[Mh] Termos MeSH secundário: Seres Humanos
Proteínas Recombinantes/uso terapêutico
Fatores de Risco
Automedicação
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Blood Coagulation Factor Inhibitors); 0 (Recombinant Proteins); AC71R787OV (recombinant FVIIa); EC 3.4.21.21 (Factor VIIa)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170809
[Lr] Data última revisão:
170809
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170608
[St] Status:MEDLINE
[do] DOI:10.1002/ajh.24811


  9 / 3778 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28565907
[Au] Autor:Güssregen S; Matter H; Hessler G; Lionta E; Heil J; Kast SM
[Ad] Endereço:R&D, IDD, Structural Design and Informatics, Sanofi-Aventis Deutschland GmbH , Industriepark Höchst, Building G877, 65926 Frankfurt am Main, Germany.
[Ti] Título:Thermodynamic Characterization of Hydration Sites from Integral Equation-Derived Free Energy Densities: Application to Protein Binding Sites and Ligand Series.
[So] Source:J Chem Inf Model;57(7):1652-1666, 2017 Jul 24.
[Is] ISSN:1549-960X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Water molecules play an essential role for mediating interactions between ligands and protein binding sites. Displacement of specific water molecules can favorably modulate the free energy of binding of protein-ligand complexes. Here, the nature of water interactions in protein binding sites is investigated by 3D RISM (three-dimensional reference interaction site model) integral equation theory to understand and exploit local thermodynamic features of water molecules by ranking their possible displacement in structure-based design. Unlike molecular dynamics-based approaches, 3D RISM theory allows for fast and noise-free calculations using the same detailed level of solute-solvent interaction description. Here we correlate molecular water entities instead of mere site density maxima with local contributions to the solvation free energy using novel algorithms. Distinct water molecules and hydration sites are investigated in multiple protein-ligand X-ray structures, namely streptavidin, factor Xa, and factor VIIa, based on 3D RISM-derived free energy density fields. Our approach allows the semiquantitative assessment of whether a given structural water molecule can potentially be targeted for replacement in structure-based design. Finally, PLS-based regression models from free energy density fields used within a 3D-QSAR approach (CARMa - comparative analysis of 3D RISM Maps) are shown to be able to extract relevant information for the interpretation of structure-activity relationship (SAR) trends, as demonstrated for a series of serine protease inhibitors.
[Mh] Termos MeSH primário: Simulação de Dinâmica Molecular
Proteínas/química
Proteínas/metabolismo
[Mh] Termos MeSH secundário: Sítios de Ligação
Proteínas Sanguíneas/química
Proteínas Sanguíneas/farmacologia
Clorobenzoatos/química
Clorobenzoatos/farmacologia
Fator VIIa/química
Fator VIIa/metabolismo
Fator Xa/química
Fator Xa/metabolismo
Inibidores do Fator Xa/química
Inibidores do Fator Xa/farmacologia
Ligantes
Ligação Proteica
Conformação Proteica
Proteínas/antagonistas & inibidores
Relação Quantitativa Estrutura-Atividade
Estreptavidina/química
Estreptavidina/metabolismo
Termodinâmica
Água/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Blood Proteins); 0 (Chlorobenzoates); 0 (Factor Xa Inhibitors); 0 (Ligands); 0 (Proteins); 0 (factor XIIa inhibitor); 059QF0KO0R (Water); 9013-20-1 (Streptavidin); EC 3.4.21.21 (Factor VIIa); EC 3.4.21.6 (Factor Xa); IC7888DF4L (4-chlorobenzoic acid)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170928
[Lr] Data última revisão:
170928
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170602
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jcim.6b00765


  10 / 3778 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28526142
[Au] Autor:Meltzer J; Guenzer JR
[Ad] Endereço:Department of Anesthesiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: Joseph.Guenzer@hsc.utah.edu.
[Ti] Título:Anticoagulant Reversal and Anesthetic Considerations.
[So] Source:Anesthesiol Clin;35(2):191-205, 2017 Jun.
[Is] ISSN:1932-2275
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bleeding complications are a common concern with the use of anticoagulant agents. In many situations, reversing of neutralizing their effects may be warranted. Prothrombin complex concentrate replaces coagulation factors lowered by warfarin, as does fresh frozen plasma, but in a more concentrated form. Protamine negates the effect of heparin and combines chemically with heparin molecules to form an inactive salt. It also partially reverses the effects of low-molecular-weight heparin. Recombinant activated factor VII is a nonspecific procoagulant that activates the extrinsic clotting pathway, resulting in thrombin generation, but does not directly neutralize the activity of any of the new oral anticoagulants.
[Mh] Termos MeSH primário: Anticoagulantes
Coagulantes/farmacologia
[Mh] Termos MeSH secundário: Anestésicos
Antitrombinas/farmacocinética
Antitrombinas/farmacologia
Fatores de Coagulação Sanguínea/farmacocinética
Fatores de Coagulação Sanguínea/farmacologia
Coagulantes/farmacocinética
Dabigatrana/farmacocinética
Dabigatrana/farmacologia
Fator VIIa/farmacocinética
Fator VIIa/farmacologia
Inibidores do Fator Xa/farmacocinética
Inibidores do Fator Xa/farmacologia
Hemorragia
Seres Humanos
Protaminas/farmacocinética
Protaminas/farmacologia
Vitamina K/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anesthetics); 0 (Anticoagulants); 0 (Antithrombins); 0 (Blood Coagulation Factors); 0 (Coagulants); 0 (Factor Xa Inhibitors); 0 (Protamines); 12001-79-5 (Vitamin K); 37224-63-8 (prothrombin complex concentrates); EC 3.4.21.21 (Factor VIIa); I0VM4M70GC (Dabigatran)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170521
[St] Status:MEDLINE



página 1 de 378 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde